Wedbush Reiterates “Neutral” Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “neutral” rating reiterated by stock analysts at Wedbush in a research note issued on Tuesday,RTT News reports. They currently have a $4.00 target price on the stock. Wedbush’s target price would indicate a potential upside of 198.51% from the company’s current price. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS and Q4 2026 earnings at ($0.33) EPS.

A number of other brokerages have also recently weighed in on ZNTL. Wall Street Zen cut Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Leerink Partners reissued a “market perform” rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $5.03.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.34 on Tuesday. The company has a fifty day moving average of $1.54 and a two-hundred day moving average of $1.45. The company has a market capitalization of $96.66 million, a PE ratio of -0.65 and a beta of 1.87. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. On average, research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after buying an additional 2,111,951 shares during the period. Acadian Asset Management LLC grew its holdings in Zentalis Pharmaceuticals by 150.6% during the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock worth $4,244,000 after acquiring an additional 1,606,802 shares during the period. Balyasny Asset Management L.P. purchased a new position in Zentalis Pharmaceuticals in the second quarter worth $1,126,000. Tybourne Capital Management HK Ltd. lifted its holdings in Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after acquiring an additional 516,666 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after purchasing an additional 515,257 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.